University of Wisconsin–Madison

Tag: aducanumab

Changing the Narrative: One Man’s Journey to Alzheimer’s Diagnosis and Treatment

Posted on

Receiving a diagnosis of Alzheimer’s disease or a related dementia can be a complicated experience. While some experience relief at being able to put a name to their concerns, many worry about telling loved ones or being treated differently due to the stigma surrounding the word “dementia.” Mike Zuendel joins the podcast to share his experience of being diagnosed with Mild Cognitive Impairment (MCI) due to Alzheimer’s disease and how he’s pushing back against the stigma surrounding dementia. He also talks about how early detection and treatment have allowed him to lead a normal life with cognitive impairment.

Guest: Mike Zuendel, member, board of directors, Banner Alzheimer’s Institute Foundation, member, Alzheimer’s Patient Advisory Board, Center for Information and Study on Clinical Research Participation, founder, Initiative to Change the D-Word, founder, CEO, Legacy Bridge Private Family Offices

Breaking Down Medicare’s Proposed Decision on Aducanumab and Monoclonal Antibody Treatments

Posted on

On January 11, the Centers for Medicare and Medicaid Services (CMS) announced its much-anticipated coverage proposal for monoclonal antibody treatments that target amyloid for the treatment of Alzheimer’s disease. According to the proposed policy, this class of drugs, which includes aducanumab, also known by the brand name Aduhelm, would be covered for people with Medicare only if they are enrolled in qualifying clinical trials. Dr. Jason Karlawish joins the podcast to discuss the recent proposal, share his reaction to the decision, and tell us how this coverage policy could impact the development of other Alzheimer’s disease treatments in the future.

Guest: Jason Karlawish, MD, co-director, Penn Memory Center, professor of medicine, medical ethics and health policy, and neurology, University of Pennsylvania

From Studying to Living with Alzheimer‘s Disease: A Conversation with Dr. Daniel Gibbs

Posted on

Neurologist and author Daniel Gibbs, PhD, joins the podcast to discuss his recent book, A Tattoo on My Brain, which details his journey from treating Alzheimer’s disease clinically for 25 years to being diagnosed with early-stage Alzheimer’s. Dr. Gibbs discusses early signs he experienced and daily life with the disease, as well as thoughts on the recent FDA-approved treatment aducanumab (marketed as Aduhelm).

Guest: Daniel Gibbs, PhD, neurologist